Physician profile
Cassandra Cavanaugh
NPI 1063581346
$8,579.96
in general payments reported to CMS, 2019-2025
23 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $629 · 2023: $734 · 2024: $3,760 · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,162 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,162.11 |
| Education | $361.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,166.99 | 2022-2025 | |
| Abbvie INC. | $1,121.32 | 2021-2025 | |
| Lilly USA, LLC | $951.04 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $790.75 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $592.14 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $502.81 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $496.90 | 2021-2025 | |
| Leo Pharma INC. | $425.49 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $388.39 | 2023-2025 | Dupixent |
| Pfizer INC. | $363.13 | 2021-2025 | |
| Galderma Laboratories, L.P. | $336.35 | 2021-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $264.78 | 2023-2025 | Zoryve |
| Ucb, INC. | $251.64 | 2023-2024 | Bimzelx |
| Organon LLC | $184.90 | 2024-2025 | Hadlima, Vtama |
| Dermavant Sciences, INC. | $154.48 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $151.99 | 2022-2024 | |
| Amgen INC. | $143.97 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $104.77 | 2024-2025 | Opzelura |
| Strata Skin Sciences, INC. | $102.81 | 2024-2025 | Xtrac |
| Fresenius Kabi USA, LLC | $24.81 | 2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.92 | 2024 | Spevigo |
| Tempus Ai, INC | $22.18 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.40 | 2025 | Clear & Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.